Survey Contents: Pharmaceuticals 2005

1. Executive Summary
2. Highlights
3. Industry Overview

3.1 Global pharmaceutical market
3.2 Segmentation of the market
3.2.1 Geographic segmentation
3.2.2 Therapeutic segmentation
3.3 Major therapeutic classes
3.4 Major products
3.5 Demand–supply
3.6 Trends shaping the pharmaceutical industry
3.6.1 Increasing consolidation
3.6.2 Increasing outsourcing market
3.6.3 Geographical shift
3.6.4 Increasing R&D costs
3.6.5 Increasing dependence on biotechnology
3.7 Conclusion
3.8 Bibliography

4. Growth Drivers

4.1 Introduction
4.2 Major growth drivers
4.2.1 Increase in aging population
4.2.2 Shifting disease patterns
4.2.3 Increasing healthcare expenditure
4.2.4 Increasing biotechnology based products
4.2.5 Direct-to-consumer advertising
4.2.6 Technological developments
4.3 Conclusion
4.4 Bibliography

5. Issues and Challenges

5.1 Introduction
5.2 Major issues and challenges
5.2.1 Decreasing R&D productivity
5.2.2 Tightened regulatory environment
5.2.3 Increase in patent expiries
5.2.4 Pricing pressure owing to intense competition
5.2.5 Realization from partnering arrangements
5.2.6 Maximizing marketing productivity
5.2.7 Parallel trade in the European Union
5.3 Conclusion
5.4 Bibliography

6. Technology

6.1 Introduction
6.2 Technology in drug development
6.2.1 Combinatorial chemistry and high throughput screening
6.2.2 Chemoinformatics
6.2.3 Medical imaging
6.2.4 Pharmacogenomics
6.3 Technology in drug delivery
6.3.1 Nanotechnology in drug delivery
6.3.2 Transdermal drug delivery
6.3.3 Chronopharmaceutical delivery
6.4 Technology in manufacturing
6.4.1 Process Analytical Technology
6.5 Technology in marketing
6.5.1 Customer relationship management
6.6 New technologies
6.6.1 Super computers in drug discovery
6.6.2 Polymorph screening
6.6.3 Microdosing in clinical trials
6.7 Conclusion
6.8 Bibliography

7. Major Markets

7.1 Introduction
7.2 US
7.2.1 Market size
7.2.2 Market segmentation
7.2.3 Major players
7.1.4 Outlook
7.2 Japan
7.2.1 Market size
7.2.2 Market segmentation
7.2.3 Outlook
7.3 Europe
7.3.1 Market size
7.3.2 Major markets
7.3.3 Outlook
7.4 UK
7.4.1 Market size
7.4.2 Market segmentation
7.4.3 Outlook
7.5 Emerging markets
7.5.1 Mexico
7.5.2 Brazil
7.5.3 China
7.6 Conclusion
7.7 Bibliography

8. Major Players

8.1 Pfizer
8.1.1 Business profile
8.1.2 Financial profile
8.1.3 Stock performance
8.1.4 Key strategies
8.1.5 Outlook
8.1.6 Intellectual property assets
8.2 Johnson & Johnson
8.2.1 Business profile
8.2.2 Financial profile
8.2.3 Stock performance
8.2.4 Key strategies
8.2.5 Outlook
8.2.6 Intellectual property assets
8.3 Glaxo SmithKline
8.3.1 Business profile
8.3.2 Financial profile
8.3.3 Stock performance
8.3.4 Key strategies
8.3.5 Outlook
8.3.6 Intellectual property assets
8.4 Sanofi-Aventis
8.4.1 Business profile
8.4.2 Financial profile
8.4.3 Stock performance
8.4.4 Key strategy
8.4.5 Outlook
8.4.6 Intellectual property assets
8.5. Novartis
8.5.1 Business profile
8.5.2 Financial profile
8.5.3 Stock performance
8.5.4 Key strategies
8.5.5 Outlook
8.5.6 Intellectual property assets
8.6 Roche
8.6.1 Business Profile
8.6.2 Financial profile
8.6.3 Stock performance
8.6.4 Key strategies
8.6.5 Outlook
8.6.6 Intellectual property assets
8.7 AstraZeneca
8.7.1 Business profile
8.7.2 Financial profile
8.7.3 Stock performance
8.7.4 Key strategies
8.7.5 Outlook
8.7.6 Intellectual property assets
8.8 Merck
8.8.1 Business profile
8.8.2 Financial profile
8.8.3 Stock performance
8.8.4 Key strategies
8.8.5 Outlook
8.8.6 Intellectual property assets
8.9 Bristol-Myers Squibb
8.9.1 Business profile
8.9.2 Financial profile
8.9.3 Stock performance
8.9.4 Key strategies
8.9.5 Outlook
8.9.6 Intellectual property assets
8.10 Wyeth
8.10.1 Business profile
8.10.2 Financial profile
8.10.3 Stock performance
8.10.4 Key strategies
8.10.5 Outlook
8.10.6 Intellectual property assets
8.11 Conclusion
8.12 Bibliography

9. Regulatory Aspects

9.1 Introduction
9.2 Regulatory bodies
9.2.1 US
9.2.2 European Union
9.2.3 Japan
9.3 Laws governing the industry
9.3.1 Regulations in the US
9.3.2 Regulations in Japan
9.3.3 Regulations in Europe
9.4 International agreements on intellectual property rights protection
9.4.1 General Agreement on Tariffs and Trade (GATT)
9.4.2 Trade Related Aspects of Intellectual Property Rights (TRIPS)
9.4.3 The Paris Convention (PCPIP)
9.4.4 The Patent Co-operation Treaty (PCT)
9.5 Prolonging Patent Protection
9.5.1 GATT and TRIPS
9.5.2 The Waxman-Hatch Act
9.6 Recent regulatory amendments
9.6.1 US
9.6.2 EU
9.6.3 Japan
9.7 Conclusion
9.8 Bibliography

10. Mergers & Acquisitions

10.1 Introduction
10.2 M&A drivers
10.2.1 Need for low cost pharmaceuticals
10.2.2 Growing generics market
10.2.3 Replenishment of decreasing R&D pipeline and shrinking patented drug list
10.2.4 Focus on areas of core competence
10.3 M&A trends
10.3.1 Pharmaceutical M&A accounted for more than one-fourth of total healthcare M&A in deal value
10.3.2 Pharmaceutical deals declined in terms of number and value in 2005
10.3.3 Smaller value deals dominated the M&A scenario in 2005
10.3.4 Top 10 M&A deals (2005, 2004 and 2003)
10.4 Impact of Hexal and Eon Labs acquisition on Sandoz (generic subsidiary of Novartis)
10.4.1 Financial impact
10.4.2 Impact on product portfolio
10.4.3 Impact on market penetration
10.5 Conclusion
10.6 Bibliography

11. Critical Success Factors

11.1 Introduction
11.2 Success factors
11.2.1 Alliances and acquisitions
11.2.2 Outsourcing to low cost destinations
11.2.3 Absorption of technological innovations
11.2.4 Improving sales force effectiveness
11.2.5 Critical mass
11.2.6 Need for blockbuster drugs
11.3 Conclusion
11.4 Bibliography

12. Future Outlook

12.1 Bibliography